Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:11:20 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:JAZZ from 2023-04-27 to 2024-04-26 - 48 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-24 16:05U:JAZZNews ReleaseJazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
2024-04-23 11:18U:JAZZNews ReleaseJazz Pharmaceuticals Employees Wear Purple To Support Epilepsy Awareness and Community
2024-04-17 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
2024-04-10 07:45U:JAZZNews ReleaseJazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
2024-04-02 07:30U:JAZZNews ReleaseJazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
2024-03-28 10:17U:JAZZNews ReleaseCancer and the Combination Approach
2024-03-20 10:18U:JAZZNews ReleaseJazz Pharmaceuticals Celebrates International Women's Day
2024-03-14 12:03U:JAZZNews ReleaseExploring How Jazz Pharmaceuticals Honored U.S. Black History Month
2024-03-12 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
2024-02-28 16:05U:JAZZNews ReleaseJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
2024-02-27 07:45U:JAZZNews ReleaseJazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
2024-02-21 07:45U:JAZZNews ReleaseJazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
2024-02-20 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
2024-02-14 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
2024-02-13 10:17U:JAZZNews ReleaseListen to How "Jazz Remix" Fosters a Positive Employee Experience at Jazz Pharmaceuticals
2024-02-09 09:16U:JAZZNews ReleaseHow This CEO Built a Top 50 Pharma Company Focusing on Culture Day 1
2024-02-07 02:00U:JAZZNews ReleaseJazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program
2023-12-21 16:05U:JAZZNews ReleaseJazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder
2023-12-20 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-08 13:20U:JAZZNews ReleaseJazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer
2023-12-08 09:17U:JAZZNews ReleaseJazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Serving our Global Communities
2023-12-01 09:02U:JAZZNews ReleaseJazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
2023-11-30 07:45U:JAZZNews ReleaseJazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings
2023-11-29 11:16U:JAZZNews ReleaseJazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Using Natural Resources Responsibly
2023-11-14 02:00U:JAZZNews ReleaseAutifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
2023-11-08 16:05U:JAZZNews ReleaseJazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
2023-11-07 07:45U:JAZZNews ReleaseJazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers
2023-11-01 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
2023-10-25 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023
2023-10-23 07:45U:JAZZNews ReleaseJazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav ‚ ® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adult
2023-10-18 07:45U:JAZZNews ReleaseJazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023
2023-10-16 07:45U:JAZZNews ReleaseJazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023
2023-10-06 10:17U:JAZZNews ReleaseJazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report Puts Patients at the Center
2023-09-21 17:41U:JAZZNews ReleaseJazz Pharmaceuticals Receives European Commission Approval for Enrylaze ‚ ® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
2023-09-13 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences
2023-09-12 07:30U:JAZZNews ReleaseJazz Pharmaceuticals Announces Key Update to Leadership Team
2023-09-11 07:45U:JAZZNews ReleaseJazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023
2023-08-24 16:23U:JAZZNews ReleaseJazz Pharmaceuticals to Participate in Citi's 18th Annual BioPharma Conference
2023-08-09 16:05U:JAZZNews ReleaseJazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance
2023-07-26 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023
2023-07-21 08:08U:JAZZNews ReleaseJazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
2023-06-02 18:41U:JAZZNews ReleaseJazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
2023-05-31 07:45U:JAZZNews ReleaseJazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023
2023-05-30 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare Conference
2023-05-25 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023
2023-05-10 16:05U:JAZZNews ReleaseJazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance
2023-05-02 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
2023-04-27 07:30U:JAZZNews ReleaseJazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023